Treatment of recurrent small cell lung cancer
- 1 April 2004
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 18 (2) , 387-416
- https://doi.org/10.1016/j.hoc.2003.12.010
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Combination Chemotherapy with Gemcitabine and Vinorelbine in the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research NetworkCancer Investigation, 2003
- Paclitaxel and gemcitabine for refractory or relapsed small cell lung cancer (SCLC). A multicentric phase II studyEuropean Journal Of Cancer, 2001
- Single-agent gemcitabine in patients with resistant small-cell lung cancerAnnals of Oncology, 2001
- Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung CancerJournal of Clinical Oncology, 2001
- Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 2000
- 1038: Topotecan (Hycamtin™) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II studyEuropean Journal Of Cancer, 1997
- Second-line chemotherapy for relapsed small cell lung cancerJapanese Journal of Clinical Oncology, 1997
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1997
- Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patientsEuropean Journal Of Cancer, 1993
- CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.Journal of Clinical Oncology, 1992